Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novartis
Woman and Man Max 99 years
Novartis Vaccines and Diagnostics Limited
Update Il y a 4 ans
A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of FLUVIRIN® [Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur], Formulation 2008-2009, when Administered to Non-Elderly Adult and Elderly Subjects
To evaluate the antibody response to each influenza vaccine antigen, as measured by Haemagglutination Inhibition (HI) test at 21 days post-immunization in non-elderly adult and elderly subjects in com...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Novartis Pharma
Update Il y a 4 ans
NOVARTIS CLBH589H2101 : essai de phase 1, en escalade de dose, visant à déterminer la dose maximale tolérée du panobinostat (LBH589) associé à du 5 -azacitidine, chez des patients ayant un syndrome myélodysplasique, une leucémle myélo-monocytaire chronique ou une leucémie aiguë myéloïde. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A phase I/b, open-label, multi-center, dose-escalation study of oral panobinostat (LBH589) administered with 5-azacitidine (Vidaza®) in adult patients with myelodysplastic syndromes (MDS), chronic mye...
Country
France
organs
Syndromes myélodysplasiques (SMD)
,
Leucémies chroniques
,
Leucémies aiguës
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman Max 99 years
Sponsored by Novartis Pharmaceuticals Corporation ( http://click.atdmt.com/GTO/go/thbmbnov00700895gto/direct/01 /)
Update Il y a 4 ans
IBS-C Study A2306
Not provided at time of registration
Country
United States
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
An eight-week, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / HCTZ (300/12.5 mg and 300/25 mg) in comparison with aliskiren 300 mg in patients with essential hypertension not adequately responsive to aliskiren 300 mg monotherapy
Demonstrate the efficacy of the combination therapy of aliskiren 300 mg and HCTZ (12.5 mg and 25 mg) in hypertensive patients who do not show sufficient blood pressure response to a 4-week treatment o...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Randomized, placebo controlled, double blind, multi-center phase II proof-of-concept study to assess the efficacy of AIN457 in patients with moderate to severe ankylosing spondylitis
Part 1: To evaluate the efficacy of AIN457 at 6 weeks based on the proportion of patients achieving an ASAS20 response Part 2: To evaluate the efficacy of lower doses of AIN457 at 6 weeks based on the...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Novartis Japan
Update Il y a 4 ans
Effect of Food on the Pharmacokinetics of AQW051 in Japanese Healthy Male Subjects
This study will evaluate safety, tolerability and pharmacokinetics of individual oral doses of AQW051 in Japanese healthy male subjects, and will also evaluate the effect of food on the ph...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis
Update Il y a 4 ans
Safety of AEB071 in Healthy Volunteers and to Compare the Ethnicity, Metabolic, and Safety Effects Between Caucasian and Japanese Healthy Subjects
This is a study to assess the safety effects after multiple doses of AEB071 in healthy volunteers and to compare the ethnicity, metabolic, and safety effects between Caucasian and Japanese...
Country
Canada
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
A single stage phase II, multi-centre, open label study of Glivec in combination with pioglitazone, etoricoxib, dexamethasone and low-dose treosulfane for anti-inflammatory and angiostatic treatment in patients with hormone-refractory prostate cancer
To investigate the effect of a treatment with Imatinib mesylate (Glivec®), Pioglitazone (Actos®), Dexamethasone (Fortecortin®) and Etoricoxib (Arcoxia®) in combination with metronomic chemotherapy (Tr...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma AG
Update Il y a 4 ans
An extension study of safety of canakinumab in Japanese patients with periodic fever syndromes
The primary objective of this study is to evaluate safety and tolerability of ACZ885 in this extension study. This extension study offers the opportunity for patients who completed Epoch 4 of the prec...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Novartis Pharma S.A.S
Update Il y a 4 ans
Etude prospective, multicentrique, randomisée, en ouvert, évaluant la progression de la fibrose rénale selon le profil de transition épithélio-mésenchymateuse chez des patients adultes transplantés rénaux de novo traités par une immunosuppression sans inhibiteur de la calcineurine associant Certican® et Myfortic® versus une immunosuppression standard associant Néoral® et Myfortic® (Etude CERTITEM)
Comparer la progression de la fibrose rénale entre le 3ème et le 12ème mois post-transplantation selon le profil de transition épithélio-mésenchymateuse (TEM) chez des patients transplantés rénaux de...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
6
7
8
9
10
11
12
13
14
15
Next